Literature DB >> 16051866

Herpes simplex virus type 1 DNA polymerase requires the mammalian chaperone hsp90 for proper localization to the nucleus.

April D Burch1, Sandra K Weller.   

Abstract

Many viruses and bacteriophage utilize chaperone systems for DNA replication and viral morphogenesis. We have previously shown that in the herpes simplex virus type 1 (HSV-1)-infected cell nucleus, foci enriched in the Hsp70/Hsp40 chaperone machinery are formed adjacent to viral replication compartments (A. D. Burch and S. K. Weller, J. Virol. 78:7175-7185, 2004). These foci have now been named virus-induced chaperone-enriched (VICE) foci. Since the Hsp90 chaperone machinery is known to engage the Hsp70/Hsp40 system in eukaryotes, the subcellular localization of Hsp90 in HSV-1-infected cells was analyzed. Hsp90 is found within viral replication compartments as well as in the Hsp70/Hsp40-enriched foci. Geldanamycin, an inhibitor of Hsp90, results in decreased HSV-1 yields and blocks viral DNA synthesis. Furthermore, we have found that the viral DNA polymerase is mislocalized to the cytoplasm in both infected and transfected cells in the presence of geldanamycin. Additionally, in the presence of an Hsp90 inhibitor, proteasome-dependent degradation of the viral polymerase was detected by Western blot analysis. These data identify the HSV-1 polymerase as a putative client protein of the Hsp90 chaperone system. Perturbations in this association appear to result in degradation, aberrant folding, and/or intracellular localization of the viral polymerase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051866      PMCID: PMC1182622          DOI: 10.1128/JVI.79.16.10740-10749.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Cloning, sequencing, and functional analysis of oriL, a herpes simplex virus type 1 origin of DNA synthesis.

Authors:  S K Weller; A Spadaro; J E Schaffer; A W Murray; A M Maxam; P A Schaffer
Journal:  Mol Cell Biol       Date:  1985-05       Impact factor: 4.272

2.  Monoclonal antibodies to herpes simplex virus type 1 proteins, including the immediate-early protein ICP 4.

Authors:  S D Showalter; M Zweig; B Hampar
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

3.  The intranuclear location of a herpes simplex virus DNA-binding protein is determined by the status of viral DNA replication.

Authors:  M P Quinlan; L B Chen; D M Knipe
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

4.  Nuclear sequestration of cellular chaperone and proteasomal machinery during herpes simplex virus type 1 infection.

Authors:  April D Burch; Sandra K Weller
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

5.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.

Authors:  Adeela Kamal; Lia Thao; John Sensintaffar; Lin Zhang; Marcus F Boehm; Lawrence C Fritz; Francis J Burrows
Journal:  Nature       Date:  2003-09-25       Impact factor: 49.962

6.  Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.

Authors:  Sonnet J H Arlander; Alex K Eapen; Benjamin T Vroman; Robert J McDonald; David O Toft; Larry M Karnitz
Journal:  J Biol Chem       Date:  2003-10-21       Impact factor: 5.157

Review 7.  Hsp70 and Hsp90--a relay team for protein folding.

Authors:  H Wegele; L Müller; J Buchner
Journal:  Rev Physiol Biochem Pharmacol       Date:  2004-01-23       Impact factor: 5.545

Review 8.  Heat shock protein 90.

Authors:  Len Neckers; S Percy Ivy
Journal:  Curr Opin Oncol       Date:  2003-11       Impact factor: 3.645

Review 9.  Clinical development of 17-allylamino, 17-demethoxygeldanamycin.

Authors:  Edward A Sausville; Joseph E Tomaszewski; Percy Ivy
Journal:  Curr Cancer Drug Targets       Date:  2003-10       Impact factor: 3.428

10.  Geldanamycin, a ligand of heat shock protein 90, inhibits the replication of herpes simplex virus type 1 in vitro.

Authors:  Yu-Huan Li; Pei-Zhen Tao; Yu-Zhen Liu; Jian-Dong Jiang
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

View more
  66 in total

1.  Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV.

Authors:  Zhiqiang Qin; Michael DeFee; Jennifer S Isaacs; Chris Parsons
Journal:  Virology       Date:  2010-05-06       Impact factor: 3.616

2.  Inhibition of heat-shock protein 90 reduces Ebola virus replication.

Authors:  Darci R Smith; Sarah McCarthy; Andrew Chrovian; Gene Olinger; Andrea Stossel; Thomas W Geisbert; Lisa E Hensley; John H Connor
Journal:  Antiviral Res       Date:  2010-05-07       Impact factor: 5.970

3.  Accumulation of oxidized proteins in Herpesvirus infected cells.

Authors:  Shomita S Mathew; Patrick W Bryant; April D Burch
Journal:  Free Radic Biol Med       Date:  2010-05-02       Impact factor: 7.376

4.  Herpes simplex virus type I disrupts the ATR-dependent DNA-damage response during lytic infection.

Authors:  Dianna E Wilkinson; Sandra K Weller
Journal:  J Cell Sci       Date:  2006-06-06       Impact factor: 5.285

5.  Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses.

Authors:  John H Connor; Margie O McKenzie; Griffith D Parks; Douglas S Lyles
Journal:  Virology       Date:  2007-01-26       Impact factor: 3.616

6.  Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance.

Authors:  Ron Geller; Marco Vignuzzi; Raul Andino; Judith Frydman
Journal:  Genes Dev       Date:  2007-01-15       Impact factor: 11.361

Review 7.  Hepatitis B virus replication.

Authors:  Juergen Beck; Michael Nassal
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

8.  Hsp40 facilitates nuclear import of the human immunodeficiency virus type 2 Vpx-mediated preintegration complex.

Authors:  Xiaogang Cheng; Michael Belshan; Lee Ratner
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

9.  Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.

Authors:  Ji Young Yoo; Brian S Hurwitz; Chelsea Bolyard; Jun-Ge Yu; Jianying Zhang; Karuppaiyah Selvendiran; Kellie S Rath; Shun He; Zachary Bailey; David Eaves; Timothy P Cripe; Deborah S Parris; Michael A Caligiuri; Jianhua Yu; Matthew Old; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2014-05-09       Impact factor: 12.531

10.  BAG3, a host cochaperone, facilitates varicella-zoster virus replication.

Authors:  Christos A Kyratsous; Saul J Silverstein
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.